U. Mueller

516 total citations
32 papers, 289 citations indexed

About

U. Mueller is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, U. Mueller has authored 32 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Genetics. Recurrent topics in U. Mueller's work include Neutropenia and Cancer Infections (11 papers), Colorectal Cancer Treatments and Studies (7 papers) and Blood disorders and treatments (7 papers). U. Mueller is often cited by papers focused on Neutropenia and Cancer Infections (11 papers), Colorectal Cancer Treatments and Studies (7 papers) and Blood disorders and treatments (7 papers). U. Mueller collaborates with scholars based in United States, Germany and Italy. U. Mueller's co-authors include Walter Pfefferle, Boxiong Tang, Jean Klášterský, Francesco Lo‐Coco, R Galeazzi, T. Christopher Bond, Bart A. Ploeger, Barbara J. Brennan, Susan Gabriel and Lynley V. Marshall and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

U. Mueller

32 papers receiving 284 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
U. Mueller United States 11 121 87 54 51 43 32 289
Meiqing Du China 6 149 1.2× 98 1.1× 48 0.9× 37 0.7× 13 0.3× 10 324
Silvia Camera Italy 10 164 1.4× 96 1.1× 67 1.2× 22 0.4× 74 1.7× 27 388
Rory L. Cochran United States 11 95 0.8× 156 1.8× 80 1.5× 45 0.9× 6 0.1× 34 481
B. Tanner Germany 13 135 1.1× 119 1.4× 21 0.4× 30 0.6× 20 0.5× 26 479
Feng-Che Kuan Taiwan 9 170 1.4× 113 1.3× 135 2.5× 13 0.3× 15 0.3× 11 438
Nanya Wang China 13 148 1.2× 150 1.7× 79 1.5× 10 0.2× 86 2.0× 29 450
Yuko Tsunoda Japan 14 256 2.1× 167 1.9× 42 0.8× 40 0.8× 27 0.6× 52 601
Elizabeth A. McCart United States 12 34 0.3× 114 1.3× 78 1.4× 11 0.2× 13 0.3× 17 384
Ulus Ali Şanlı Türkiye 13 172 1.4× 186 2.1× 97 1.8× 26 0.5× 6 0.1× 49 460

Countries citing papers authored by U. Mueller

Since Specialization
Citations

This map shows the geographic impact of U. Mueller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Mueller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Mueller more than expected).

Fields of papers citing papers by U. Mueller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Mueller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Mueller. The network helps show where U. Mueller may publish in the future.

Co-authorship network of co-authors of U. Mueller

This figure shows the co-authorship network connecting the top 25 collaborators of U. Mueller. A scholar is included among the top collaborators of U. Mueller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Mueller. U. Mueller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
El-Khoueiry, Anthony B., Tae‐You Kim, Jean‐Frédéric Blanc, et al.. (2024). International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology. 42(16_suppl). 4007–4007. 13 indexed citations
2.
Casanova, Michela, Francisco Bautista, Guy Makin, et al.. (2023). Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study. Clinical Cancer Research. 29(21). 4341–4351. 19 indexed citations
3.
Geoerger, Birgit, Bruce Morland, Irène Jiménez, et al.. (2021). Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. European Journal of Cancer. 153. 142–152. 14 indexed citations
4.
El-Khoueiry, Anthony B., Richard D. Kim, William Proctor Harris, et al.. (2021). Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 39(15_suppl). 4078–4078. 15 indexed citations
5.
Kim, Richard D., William Proctor Harris, Max W. Sung, et al.. (2021). Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 39(3_suppl). 323–323. 4 indexed citations
6.
Galle, Peter R., Max W. Sung, William Proctor Harris, et al.. (2020). 990P Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Annals of Oncology. 31. S691–S692. 9 indexed citations
7.
Casanova, Michela, Francisco Bautista, Quentin Campbell Hewson, et al.. (2020). Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 10507–10507. 6 indexed citations
8.
Abboud, Camille N., Henry C. Fung, Anton Buchner, et al.. (2018). Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors. Supportive Care in Cancer. 27(7). 2569–2577. 12 indexed citations
9.
Renouf, Daniel J., Hal W. Hirte, Cindy L. O’Bryant, et al.. (2016). A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI). Annals of Oncology. 27. vi167–vi167. 1 indexed citations
10.
11.
Pettengell, Ruth, et al.. (2016). Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. Supportive Care in Cancer. 24(6). 2677–2684. 5 indexed citations
12.
Szende, Ágota, Jason C. Allaire, Marco Petti, et al.. (2016). Budgetary impact of lipegfilgrastim to the Brazilian public healthcare system.. Journal of Clinical Oncology. 34(15_suppl). e14072–e14072. 1 indexed citations
13.
Mueller, U., et al.. (2015). Lipegfilgrastim For Reduction Of Chemotherapy-Induced Neutropenia Related Events: A Meta-Analysis. Value in Health. 18(7). A434–A434. 3 indexed citations
14.
Tallman, Martin S., et al.. (2015). Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. Clinical Lymphoma Myeloma & Leukemia. 15(12). 771–777. 17 indexed citations
15.
16.
Pukac, Laurie, Steven Barash, Noa Avisar, et al.. (2013). Balugrastim: A long-acting, once-per-cycle, recombinant human albumin-fusion filgrastim.. Journal of Clinical Oncology. 31(15_suppl). e13551–e13551. 2 indexed citations
17.
Volovăț, Constantin, et al.. (2012). Efficacy and safety of lipegfilgrastim in elderly patients with non-small-cell lung cancer receiving cisplatin/etoposide chemotherapy. Journal of Geriatric Oncology. 3. S97–S98. 3 indexed citations
18.
Mueller, U., et al.. (2002). Economic Aspects of Amino Acids Production. Advances in biochemical engineering, biotechnology. 79. 137–170. 19 indexed citations
19.
Baumann, Hanno, U. Mueller, & R. Keller. (1997). Which Glycosaminoglycans Are Suitable for Antithrombogenic or Athrombogenic Coatings of Biomaterials? Part I: Basic Concepts of Immobilized GAGs on Partially Cationized Cellulose Membrane. Seminars in Thrombosis and Hemostasis. 23(2). 203–213. 6 indexed citations
20.
Mueller, U., et al.. (1995). Diuretic-related hypokalaemia: the role of diuretics, potassium supplements, glucocorticoids and ?2-adrenoceptor agonists. European Journal of Clinical Pharmacology. 49(1-2). 31–6. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meiqing Du Breakdown of academic impact, for papers by Silvia Camera Breakdown of academic impact, for papers by Rory L. Cochran Breakdown of academic impact, for papers by B. Tanner Breakdown of academic impact, for papers by Feng-Che Kuan Breakdown of academic impact, for papers by Nanya Wang Breakdown of academic impact, for papers by Yuko Tsunoda Breakdown of academic impact, for papers by Elizabeth A. McCart Breakdown of academic impact, for papers by Ulus Ali Şanlı
Rankless by CCL
2026